Email this article Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy
- Authors: Goldberg V.E.1, Polyakova T.Y.2,3, Popova N.O.1, Vysotskaya V.V.1, Simolina E.I.1, Dudnikova E.A.1, Goncharova N.M.1, Belevich Y.V.1, Tuzikova T.P.2, Goldberg A.V.1, Miroshnichenko L.A.2, Udut E.V.2, Simanina E.V.2, Zyuz’kov G.N.2, Zhdanov V.V.2, Dygai A.M.1
-
Affiliations:
- Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
- National Research Tomsk State University
- Issue: Vol 166, No 1 (2018)
- Pages: 63-68
- Section: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/240835
- DOI: https://doi.org/10.1007/s10517-018-4290-8
- ID: 240835
Cite item
Open Access
Access granted
Subscription Access
Abstract
We studied myelotoxicity of modern schemes of chemotherapy for breast cancer (docetaxel/doxorubicin and cyclophosphamide/doxorubicin/5-fluorouracil) towards granulocytopoiesis, the mechanisms determining the differences of hematological effects of these schemes, and the efficiency of correction of the observed changes with granulocyte CSF (filgrastim). Granulocytopoiesis stimulation with filgrastim during the treatment with docetaxel/doxorubicin combination was more pronounced than during cyclophosphamide/doxorubicin/5-fluorouracil therapy. The observed differences were found at all levels of granulocyte lineage organization (central and peripheral), which is related to different effects of the cytostatic substances used in the proposed protocols on the structures controlling hemopoiesis.
About the authors
V. E. Goldberg
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Author for correspondence.
Email: center@tnimc.ru
Russian Federation, Tomsk
T. Yu. Polyakova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences; National Research Tomsk State University
Email: center@tnimc.ru
Russian Federation, Tomsk; Tomsk
N. O. Popova
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
V. V. Vysotskaya
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
E. I. Simolina
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
E. A. Dudnikova
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
N. M. Goncharova
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
Yu. V. Belevich
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
T. P. Tuzikova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
A. V. Goldberg
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
L. A. Miroshnichenko
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
E. V. Udut
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
E. V. Simanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
G. N. Zyuz’kov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
V. V. Zhdanov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
A. M. Dygai
Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences
Email: center@tnimc.ru
Russian Federation, Tomsk
Supplementary files
